I just received a similar email today from her. I responded asking if the fact we haven’t heard much about the preliminary results it means the results were not positive and if I get a response I will let you all know .
Would be nice to have positive results but not expecting much at this point
Sleven posted it in a negative light. The response I got did not. There was no mention of positive or negative results just that they were presented in October
Looks like Sleven/Pdude had correct info. It's a bummer. Hopefully there might still be some hints in the fully analyzed data. For my part, I'm curious if the cohort studied was too healthy and there was a lack of meaningful clinical progression. Of course, I was really hoping the IPE arm would show improvements from baseline, so that a positive readout wouldn't rely on the placebo arm getting much worse.
Here's a look at PACC scores for pre-clinical patients (so a similar risk cohort to Brave) in the failed A4 study. Brave would only be at the 78 week mark, to give a sense comparison.
I believe most of the recent headline making Alz trails these past years have been in patients with mild cognitive decline, and "success" is measured by how much they slow that decline, rather than actual improvements to cognition.
News 
Market Data 
Discover 
